DICER1 Syndrome: Characterization of the Ocular Phenotype in a Family-Based Cohort Study.
Adolescent
Adult
Aged
Case-Control Studies
Child
Child, Preschool
Ciliary Body
/ pathology
DEAD-box RNA Helicases
/ biosynthesis
DNA, Neoplasm
/ genetics
Electroretinography
/ methods
Female
Gene Expression Regulation, Neoplastic
Genetic Predisposition to Disease
Humans
Infant
Male
Middle Aged
Neuroectodermal Tumors, Primitive
/ diagnosis
Phenotype
Prospective Studies
Retinal Pigment Epithelium
/ pathology
Ribonuclease III
/ biosynthesis
Slit Lamp Microscopy
Syndrome
Tomography, Optical Coherence
/ methods
Uveal Neoplasms
/ diagnosis
Visual Acuity
Young Adult
Journal
Ophthalmology
ISSN: 1549-4713
Titre abrégé: Ophthalmology
Pays: United States
ID NLM: 7802443
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
22
03
2018
revised:
22
09
2018
accepted:
25
09
2018
pubmed:
20
10
2018
medline:
30
11
2019
entrez:
20
10
2018
Statut:
ppublish
Résumé
To characterize the ocular phenotype of DICER1 syndrome. Prospective, single-center, case-control study. One hundred three patients with an identified germline pathogenic DICER1 variant (DICER1 carriers) and 69 family control participants underwent clinical and ophthalmic examination at the National Institutes of Health between 2011 and 2016. All participants were evaluated with a comprehensive ophthalmic examination, including best-corrected visual acuity, slit-lamp biomicroscopy, and a dilated fundus examination. A subset of patients returned for a more detailed evaluation including spectral-domain OCT, color fundus photography, fundus autofluorescence imaging, visual field testing, full-field electroretinography, and genetic testing for inherited retinal degenerative diseases. Visual acuity and examination findings. Most DICER1 carriers (97%) maintained a visual acuity of 20/40 or better in both eyes. Twenty-three DICER1 carriers (22%) showed ocular abnormalities compared with 4 family controls (6%; P = 0.005). These abnormalities included retinal pigment abnormalities (n = 6 [5.8%]), increased cup-to-disc ratio (n = 5 [4.9%]), optic nerve abnormalities (n = 2 [1.9%]), epiretinal membrane (n = 2 [1.9%]), and drusen (n = 2 [1.9%]). Overall, we observed a significant difference (P = 0.03) in the rate of retinal abnormalities in DICER1 carriers (n = 11 [11%]) versus controls (n = 1 [1.5%]). One patient demonstrated an unexpected diagnosis of retinitis pigmentosa with a novel variant of unknown significance in PRPF31, and 1 showed optic nerve elevation in the setting of increased intracranial pressure (ICP) of unclear cause. Three patients (3%) demonstrated DICER1-related ciliary body medulloepithelioma (CBME), 2 of which were identified during routine examination, a higher rate than that reported previously. Ophthalmologists should be aware of the ophthalmic manifestations of DICER1 syndrome, and individuals and families should be counseled on the potential signs and symptoms. We recommend that children with a germline pathogenic variant in DICER1, especially those younger than 10 years, undergo annual dilated ophthalmic examination, looking for evidence of CBME, signs of increased ICP, and perhaps changes in the retinal pigment epithelium.
Identifiants
pubmed: 30339877
pii: S0161-6420(18)30808-X
doi: 10.1016/j.ophtha.2018.09.038
pmc: PMC6348055
mid: NIHMS1511551
pii:
doi:
Substances chimiques
DNA, Neoplasm
0
DICER1 protein, human
EC 3.1.26.3
Ribonuclease III
EC 3.1.26.3
DEAD-box RNA Helicases
EC 3.6.4.13
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
296-304Subventions
Organisme : NCI NIH HHS
ID : R01 CA143167
Pays : United States
Organisme : Intramural NIH HHS
ID : Z99 CA999999
Pays : United States
Organisme : Intramural NIH HHS
ID : Z99 EY999999
Pays : United States
Informations de copyright
Published by Elsevier Inc.
Références
Doc Ophthalmol. 2009 Feb;118(1):69-77
pubmed: 19030905
Clin Cancer Res. 2017 Jun 15;23(12):e76-e82
pubmed: 28620008
Science. 2009 Aug 21;325(5943):965
pubmed: 19556464
Doc Ophthalmol. 2015 Feb;130(1):1-12
pubmed: 25502644
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
J Clin Endocrinol Metab. 2017 May 1;102(5):1614-1622
pubmed: 28323992
FASEB J. 2014 Aug;28(8):3780-91
pubmed: 24812086
Acta Neuropathol. 2014 Jul;128(1):111-22
pubmed: 24839956
Nature. 2011 Mar 17;471(7338):325-30
pubmed: 21297615
Nat Rev Cancer. 2014 Oct;14(10):662-72
pubmed: 25176334
Pediatr Dev Pathol. 2015 Nov-Dec;18(6):504-11
pubmed: 26698637
FASEB J. 2016 Jan;30(1):23-33
pubmed: 26399786
J Ophthalmol. 2015;2015:309510
pubmed: 26124959
Nucleic Acids Res. 2016 Jan 4;44(D1):D862-8
pubmed: 26582918
Retina. 2015 May;35(5):957-65
pubmed: 25545484
Development. 2015 Jul 15;142(14):2487-98
pubmed: 26062936
Ophthalmology. 2013 Dec;120(12):2552-2559
pubmed: 23796765
Br J Ophthalmol. 2011 Jul;95(7):1001-5
pubmed: 21156700
Clin Cancer Res. 2018 May 15;24(10):2251-2261
pubmed: 29343557
Clin Genet. 2016 Aug;90(2):118-26
pubmed: 26853529
Cancer. 2015 Jan 15;121(2):276-85
pubmed: 25209242
Hum Pathol. 2015 May;46(5):783-7
pubmed: 25791583
J Med Genet. 2012 Jul;49(7):417-9
pubmed: 22717647
Genome Res. 2001 May;11(5):863-74
pubmed: 11337480
Genet Med. 2017 Feb;19(2):244-248
pubmed: 27441995
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
Surv Ophthalmol. 2002 Nov-Dec;47(6):515-32
pubmed: 12504737